HC Wainwright Raises Earnings Estimates for Prime Medicine

Prime Medicine, Inc. (NASDAQ:PRME – Free Report) – Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Prime Medicine in a research note issued on Monday, November 16th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.99) per share for the year, up from their previous estimate of ($1.11). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Prime Medicine’s Q4 2026 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($0.94) EPS and FY2030 earnings at ($0.80) EPS.

A number of other research firms have also weighed in on PRME. Citigroup reaffirmed a “market outperform” rating on shares of Prime Medicine in a report on Friday, September 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prime Medicine in a report on Monday, August 31st. BMO Capital Markets initiated coverage on shares of Prime Medicine in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 price objective for the company. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Prime Medicine in a research report on Friday, September 25th. Finally, Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.86.

Check Out Our Latest Stock Report on PRME

Prime Medicine Price Performance

NASDAQ PRME opened at $3.84 on Wednesday. The company’s fifty day simple moving average is $3.73 and its 200-day simple moving average is $3.51. Prime Medicine has a 52 week low of $2.67 and a 52 week high of $5.91.

Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $4.21 million during the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 286.97%.

Institutional Trading of Prime Medicine

A number of hedge funds have recently made changes to their positions in PRME. Alphabet Inc. bought a new stake in shares of Prime Medicine in the 2nd quarter worth about $61,116,000. BlackRock Inc. acquired a new stake in shares of Prime Medicine in the 2nd quarter valued at about $35,432,000. ADAR1 Capital Management LLC bought a new position in shares of Prime Medicine during the second quarter worth about $7,371,000. Redmile Group LLC bought a new position in shares of Prime Medicine during the first quarter worth about $5,536,000. Finally, Bank of America Corp DE acquired a new position in Prime Medicine in the second quarter worth about $3,621,000. Institutional investors and hedge funds own 70.37% of the company’s stock.

Key Prime Medicine News

Investors following PRME have been watching these news items:

  • Positive Sentiment: HC Wainwright raised several EPS forecasts, implying smaller expected losses. Notable revisions include FY2026 to ($0.99) from ($1.11), Q4 2026 to ($0.26) from ($0.32), and FY2027 to ($0.89) from ($0.91). It maintained its Buy rating and $8 price target. These forecast improvements could support investor sentiment, though Prime Medicine is still expected to report losses. HC Wainwright estimate updates
  • Positive Sentiment: HC Wainwright separately reaffirmed its Buy rating and $8 price target for PRME, adding support to the positive analyst view. Prime Medicine stock rating reaffirmed as Buy
  • Neutral Sentiment: Prime Medicine presented at the Jefferies Global Healthcare Conference on November 16. The provided transcript listing contains no specific statements or announcements to assess as a stock catalyst. Jefferies conference transcript

About Prime Medicine

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

Recommended Stories

Earnings History and Estimates for Prime Medicine (NASDAQ:PRME)

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.